[Part I — Financial Information](index=3&type=section&id=Part%20I%20%E2%80%94%20Financial%20Information) [Financial Statements (Unaudited)](index=4&type=section&id=Item%201%2E%20Financial%20Statements%20%28Unaudited%29) PDS Biotechnology reported a $21.2 million net loss for H1 2023, with cash and assets declining due to R&D investment [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheet Highlights (Unaudited) | Account | June 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $60,624,991 | $73,820,160 | | Total current assets | $63,350,949 | $76,480,390 | | **Total assets** | **$63,754,250** | **$77,007,923** | | **Liabilities & Equity** | | | | Total current liabilities | $7,904,189 | $9,821,036 | | Note payable, net of debt discount | $23,254,367 | $23,020,844 | | **Total liabilities** | **$31,310,061** | **$33,005,893** | | Accumulated deficit | $(122,753,230) | $(101,558,417) | | **Total stockholders' equity** | **$32,444,189** | **$44,002,030** | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Statement of Operations Summary (Unaudited) | Metric | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | Research and development expenses | $8,004,852 | $3,761,646 | $13,848,538 | $8,922,961 | | General and administrative expenses | $4,691,321 | $3,331,006 | $8,270,049 | $6,648,913 | | Loss from operations | $(12,696,173) | $(7,092,652) | $(22,118,587) | $(15,571,874) | | **Net loss and comprehensive loss** | **$(11,534,895)** | **$(5,819,200)** | **$(21,194,813)** | **$(14,292,722)** | | Net loss per share, basic and diluted | $(0.37) | $(0.20) | $(0.69) | $(0.50) | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash Flow Summary (Unaudited) | Cash Flow Activity | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | $(18,003,030) | $(12,287,867) | | Net cash provided by financing activities | $4,807,861 | $29,917 | | **Net increase in cash and cash equivalents** | **$(13,195,169)** | **$(12,257,950)** | | Cash and cash equivalents at end of period | $60,624,991 | $52,984,672 | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) - The company is a clinical-stage immunotherapy firm developing treatments for cancer and infectious diseases using its Versamune, Infectimune, and PDS0301 platforms, which are designed to activate potent T cells[20](index=20&type=chunk) - As of June 30, 2023, the company had **$60.6 million** in cash and cash equivalents, and management believes these funds are sufficient to continue operations and R&D programs for at least 12 months from the filing date of this report[36](index=36&type=chunk)[44](index=44&type=chunk) - In August 2022, the company entered into a venture loan agreement for up to six term loans, receiving funds from Loans A, B, C, and D on August 24, 2022, with floating interest rates and a 48-month maturity[40](index=40&type=chunk)[71](index=71&type=chunk) - In January 2023, the company entered into an exclusive global license agreement with Merck KGaA for the tumor-targeting antibody M9241 (now PDS0301), with potential milestone payments up to **$11 million** for development/first commercial sale and up to **$105 million** based on sales levels, plus a **10% royalty** on net sales[67](index=67&type=chunk)[68](index=68&type=chunk) - The company sold New Jersey Net Operating Loss (NOL) carryforwards, resulting in an income tax benefit of **$1.4 million** and **$1.2 million** for the six months ended June 30, 2023 and 2022, respectively[65](index=65&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=18&type=section&id=Item%202%2E%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management highlights clinical pipeline progress and increased R&D expenses, ending Q2 2023 with **$60.6 million** cash deemed sufficient for 12 months [Company Overview and Recent Developments](index=19&type=section&id=Company%20Overview%20and%20Recent%20Developments) - PDS Biotech is a clinical-stage immunotherapy company focused on activating T cells to treat cancer and infectious diseases through its Versamune®, Infectimune®, and PDS0301 platforms[87](index=87&type=chunk) - In June 2022, the FDA granted Fast Track designation to the lead candidate, PDS0101, in combination with Merck's KEYTRUDA® for treating recurrent/metastatic HPV16-positive head and neck cancer[88](index=88&type=chunk) - In December 2022, the company executed an exclusive global license agreement with Merck KGaA for the tumor-targeting IL-12 agent M9241, now designated PDS0301[92](index=92&type=chunk) - In February 2023, the company successfully completed a Type B meeting with the FDA regarding a potential registrational trial for the triple combination of PDS0101, PDS0301, and an approved checkpoint inhibitor for ICI-refractory head and neck cancer[93](index=93&type=chunk) [Clinical Candidate Pipeline](index=20&type=section&id=Clinical%20Candidate%20Pipeline) - **VERSATILE-002 (PDS0101 + KEYTRUDA®):** Enrollment in the ICI-naïve arm was completed in May 2023, with plans to initiate a Phase 3 trial (VERSATILE-003) in Q4 2023[95](index=95&type=chunk)[102](index=102&type=chunk) VERSATILE-002 ICI-Naïve Cohort Data (ASCO June 2023) | Metric | Result | | :--- | :--- | | Estimated 12-month overall survival rate | 87.1% | | Median progression-free survival | 10.4 months | | Objective response rate (confirmed & unconfirmed) | 41.2% (14/34 patients) | | Disease control rate | 70.6% (24/34 patients) | | Grade 3 treatment-related adverse events | 8.3% (4/48 patients) | - **NCI Triple Combination Trial (PDS0101 + PDS0301):** In ICI-refractory patients, the trial demonstrated a median overall survival of **21 months**, significantly better than the historical 3-4 months, with an objective response rate of **63%** at the optimal dose[106](index=106&type=chunk)[110](index=110&type=chunk) - **IMMUNOCERV Trial (PDS0101 + Chemoradiotherapy):** In patients with locally advanced cervical cancer, **100% (9/9)** showed an objective response, with **89% (8/9)** achieving a complete response, and the 1-year disease-free and overall survival was **89%**[111](index=111&type=chunk)[113](index=113&type=chunk) [Results of Operations](index=27&type=section&id=Results%20of%20Operations) Comparison of Operating Results (in thousands) | Period | Research & Development (in thousands) | General & Administrative (in thousands) | Net Loss (in thousands) | | :--- | :--- | :--- | :--- | | **Three Months Ended June 30, 2023** | **$8,005** | **$4,691** | **$(11,535)** | | Three Months Ended June 30, 2022 | $3,762 | $3,331 | $(5,819) | | **Six Months Ended June 30, 2023** | **$13,849** | **$8,270** | **$(21,195)** | | Six Months Ended June 30, 2022 | $8,923 | $6,649 | $(14,293) | - R&D expenses for the three and six months ended June 30, 2023 increased by **$4.2 million** and **$4.9 million** YoY, respectively, driven by higher costs for clinical trials, personnel (including stock-based compensation), and manufacturing[138](index=138&type=chunk)[142](index=142&type=chunk) - G&A expenses for the three and six months ended June 30, 2023 increased by **$1.4 million** and **$1.6 million** YoY, respectively, primarily due to increased personnel costs (including stock-based compensation) and professional fees[139](index=139&type=chunk)[143](index=143&type=chunk) [Liquidity and Capital Resources](index=29&type=section&id=Liquidity%20and%20Capital%20Resources) - The company had **$60.6 million** in cash and cash equivalents as of June 30, 2023[153](index=153&type=chunk) - Management believes existing cash is sufficient to fund operations and R&D programs for 12 months following the filing of this report[154](index=154&type=chunk)[160](index=160&type=chunk) - During the six months ended June 30, 2023, the company sold **576,462 shares** of common stock for net proceeds of **$4.8 million** under its At Market Issuance Sales Agreement[148](index=148&type=chunk) - In April 2023, the company received approximately **$1.4 million** from the net sale of tax benefits through the New Jersey NOL program for tax year 2021[152](index=152&type=chunk) Summary of Cash Flows (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2023 (in thousands) | Six Months Ended June 30, 2022 (in thousands) | | :--- | :--- | :--- | | Net cash used in operating activities | $(18,003) | $(12,288) | | Net cash provided by financing activities | $4,808 | $30 | | Net increase in cash and cash equivalents | $(13,195) | $(12,258) | [Quantitative and Qualitative Disclosures About Market Risk](index=32&type=section&id=Item%203%2E%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate fluctuation, though management expects no material impact from rate changes or inflation - The company is exposed to market risk from interest rate fluctuations on its cash equivalents and variable interest rate debt[169](index=169&type=chunk) - Management does not expect operating results or cash flows to be materially affected by a sudden change in market interest rates[169](index=169&type=chunk) - Inflation has not had a material effect on the company's business, financial condition, or results of operations during the quarter[170](index=170&type=chunk) [Controls and Procedures](index=32&type=section&id=Item%204%2E%20Controls%20and%20Procedures) Management concluded disclosure controls were effective as of June 30, 2023, with no material changes to internal control over financial reporting - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of the end of the period covered by the report[171](index=171&type=chunk) - No changes in internal control over financial reporting occurred during the quarter ended June 30, 2023, that have materially affected, or are reasonably likely to materially affect, internal controls[173](index=173&type=chunk) [Part II — Other Information](index=34&type=section&id=Part%20II%20%E2%80%94%20Other%20Information) [Legal Proceedings](index=34&type=section&id=Item%201%2E%20Legal%20Proceedings) The company is not currently a party to any material pending legal proceedings - The company is not a party to any material pending legal proceedings[69](index=69&type=chunk)[174](index=174&type=chunk) [Risk Factors](index=34&type=section&id=Item%201A%2E%20Risk%20Factors) There have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K for the year ended December 31, 2022 - No material changes have occurred in the company's risk factors since the filing of its Annual Report on Form 10-K for the year ended December 31, 2022[175](index=175&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=34&type=section&id=Item%202%2E%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) In April 2023, the company issued **100,000** unregistered common shares valued at **$659,000** to DC Consulting LLC for services - In April 2023, the company issued **100,000** unregistered shares of common stock to DC Consulting LLC for consulting services, with a fair value of approximately **$659,000** at issuance[176](index=176&type=chunk) [Other Information](index=34&type=section&id=Item%205%2E%20Other%20Information) During the quarter ended June 30, 2023, no directors or officers adopted, terminated, or modified a Rule 10b5-1 trading arrangement - No directors or officers adopted, terminated, or modified a Rule 10b5-1 trading arrangement during the quarter[179](index=179&type=chunk) [Exhibits](index=34&type=section&id=Item%206%2E%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including certifications by the Principal Executive Officer and Principal Financial Officer as required by the Sarbanes-Oxley Act of 2002, and XBRL data files - The report includes required certifications from the CEO and CFO under Sections 302 and 906 of the Sarbanes-Oxley Act[183](index=183&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _____________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) (State or oth ...

Financial Data and Key Metrics Changes - The net loss for Q1 2023 was approximately $9.7 million or $0.32 per share, compared to a net loss of $8.5 million or $0.32 per share for the same period in 2022, attributed to increased personnel costs, clinical studies costs, and medical affairs expenses [20][21]. - Total operating expenses for Q1 2023 were approximately $9.4 million, up from approximately $8.5 million in Q1 2022 [21]. - The company ended the quarter with approximately $65.2 million in cash, with cash burn impacted by a $5 million payment to Merck KGaA for the in-license of PDS0301 [22]. Business Line Data and Key Metrics Changes - Research and development expenses for Q1 2023 increased to approximately $5.8 million from $5.2 million in Q1 2022, primarily due to increased clinical studies and personnel costs [43]. - General and administrative expenses for Q1 2023 increased slightly to approximately $3.6 million from $3.3 million in Q1 2022, mainly due to higher personnel costs [97]. Market Data and Key Metrics Changes - The company is preparing to initiate the Phase 3 VERSATILE-003 trial, which will study PDS0101 in combination with KEYTRUDA against KEYTRUDA monotherapy in HPV-positive cancers [5][39]. - The Phase 2 results of PDS0101 have shown consistent anti-tumor activity across various HPV-positive cancers, with substantial biomarker data indicating the induction of HPV16-specific killer T cells [38]. Company Strategy and Development Direction - The company aims to commercialize PDS0101 for first-line treatment of recurrent or metastatic HPV-positive head and neck cancer, addressing a significant unmet medical need [14]. - The strategic focus includes the development of a triple combination therapy involving PDS0101, PDS0301, and a commercial immune checkpoint inhibitor, with promising results in both ICI naive and refractory cancers [17][55]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, emphasizing the potential of PDS0101 to revolutionize cancer treatment and the importance of upcoming milestones [14][87]. - The company is awaiting feedback from the FDA regarding the VERSATILE-003 trial design and anticipates that initial data from the refractory arm of the VERSATILE-002 study will inform the registrational study design [40][77]. Other Important Information - The company has monetized its net operating loss carryforwards in New Jersey, receiving $1.4 million as part of a tax benefits program [44]. - The company plans to present updated interim results for the Phase 2 VERSATILE-002 trial at the ASCO conference, which has been accepted for a poster presentation [37][72]. Q&A Session Summary Question: Can you provide more thoughts on the expert panel reviewing the VERSATILE-002 study at ASCO? - Management indicated that the expert panel will assess the data presented, including interim data points for progression-free survival (PFS) and overall survival (OS) [23][26]. Question: What are the expectations for interim analysis in the VERSATILE-003 trial? - Management stated that interim analysis criteria will be established in alignment with the FDA, and they are designing the trial based on observed enrollment rates from VERSATILE-002 [46][68]. Question: Can you discuss the partnership environment and ongoing discussions? - Management confirmed that partnership discussions are ongoing and are facilitated by the progress into Phase 3 trials, which potential partners find attractive [82]. Question: What is the anticipated cash burn for the remainder of the year? - Management projected a cash burn ramp-up to approximately $12 million to $13 million per quarter, primarily driven by R&D expenses [94]. Question: What CMC-related work is still needed before filing an amended IND? - Management highlighted the need for proper characterization of the manufacturing and release processes, as well as stability program requirements before filing the IND in Q3 [73][74].

Immunotherapy Development - The company is developing a pipeline of targeted cancer and infectious disease immunotherapies based on proprietary platforms Versamune® and Infectimune™, aiming to induce large quantities of high-quality CD4 and CD8 T cells[17]. - The company aims to address a wide range of cancers, including HPV-positive cancers and various solid tumors[17]. - The company is focused on overcoming challenges in immunotherapy, such as generating adequate quantities of high-quality T cells and minimizing systemic toxicities[23]. - The combination of Versamune and IL-12 is patented by the company, streamlining the registrational process for its therapies[21]. - Versamune has shown the ability to reduce the Treg to CD8 T cell ratio, enhancing tumor susceptibility to immune destruction[39]. - In preclinical studies, Versamune-based therapy resulted in complete tumor regression after a single subcutaneous injection[52]. - PDS0101 demonstrated immunological activity at all three doses studied, leading to clinical regression of cervical lesions in patients[52]. - PDS0301, when combined with Versamune, has shown potential for significant disease control by shrinking tumors and prolonging patient survival[58]. - PDS0102 is designed to treat TARP-associated cancers, showing safety and immunogenicity in preclinical studies[87]. - PDS Biotech is developing a universal influenza vaccine using the Infectimune platform, aiming for broad protection against multiple strains[63]. - PDS0201 is in preclinical development targeting tuberculosis, a leading cause of death from a single infectious agent, with 1.5 million deaths reported in 2020[66]. Clinical Trials and Results - In a Phase 2 clinical trial, the combination of PDS0101 and PDS0301 resulted in a median overall survival of 21 months for ICI refractory head and neck cancer patients, compared to a historical median survival of 3-4 months with checkpoint inhibitors[21]. - The VERSATILE-002 Phase 2 clinical trial is actively recruiting patients to evaluate the combination of PDS0101 and KEYTRUDA® for recurrent/metastatic head and neck cancer[71]. - Preliminary efficacy data from the VERSATILE-002 trial showed an objective response rate of at least 23.5% in the ICI refractory group[79]. - In the NCI-led Phase 2 trial, 41.2% of patients achieved tumor shrinkage greater than 30% with the triple combination therapy[78]. - The median overall survival for ICI refractory patients receiving the triple combination therapy was reported at 21 months, compared to historical data of 3-4 months[82]. - In ICI naïve patients, the objective response rate with the triple combination was 88%, significantly higher than the less than 25% reported with FDA-approved ICIs[82]. - The ongoing Phase 2 trial with MD Anderson Cancer Center is investigating the combination of PDS0101 with standard-of-care chemoradiotherapy for locally advanced cervical cancer[84]. - PDS0101 treatment resulted in 100% objective response rate and 89% complete response rate in patients treated with combination therapy[88]. - 1-year disease-free survival and overall survival rates were both 89% in patients receiving PDS0101 combined with CRT[88]. - Safety data from the trials indicate that 48% of patients experienced Grade 3 treatment-related adverse events, with no Grade 5 events reported[82]. Regulatory and Financial Aspects - The FDA granted Fast Track designation to PDS0101 in combination with KEYTRUDA® to expedite its development for serious conditions[18]. - The next step for PDS0101 is transitioning into Phase 3 clinical development, with an amended IND filing planned for Q3 2023[108]. - The company plans to progress PDS0102 and PDS0103 to IND submissions in 2023 for first-in-human trials[109]. - The company has not generated any product revenue to date and has incurred net losses each year since inception[100]. - The biotechnology and pharmaceutical industries are characterized by intense competition, with established companies and development-stage biotechnology companies competing in immunotherapies and vaccines[134]. - PDS anticipates facing increasing competition as new immunotherapies enter the market, which may affect its ability to compete based on efficacy, safety, and pricing[136]. - The FDA approval process for biological drug products requires substantial time and financial resources, with various regulatory steps that must be completed before marketing[138]. - The FDA may impose a clinical hold or partial clinical hold on clinical trials, which delays or suspends investigations, with a written explanation provided within 30 days[143]. - The company is seeking nondilutive financing to support the next stage of clinical development for its product candidates[97]. Intellectual Property and Agreements - As of December 31, 2022, the company holds seven (7) U.S. patents and nineteen (19) pending U.S. patent applications related to its Versamune platform, with issued patents expiring between 2026 and 2033[111]. - The company has an exclusive worldwide license from Merck & Cie for (R)-DOTAP and its related pharmaceutical compositions, which are significant for its immunotherapy products[112]. - The company has licensed patented antigens from the U.S. government for use in cationic lipid immunotherapies, including TARP peptide-based therapies for prostate and breast cancers[113]. - A non-exclusive agreement was entered into with the University of Georgia Research Foundation to develop COBRA universal influenza antigens for a clinical trial of a universal influenza vaccine[114]. - On December 30, 2022, the company entered into a License Agreement with Merck KGaA, which includes a one-time cash payment of $5.0 million and the issuance of 378,787 shares valued at $5.0 million[116]. - The company agreed to make milestone payments totaling up to $11 million upon achieving certain development milestones and up to $105 million based on aggregate sales levels of the product under the Merck KGaA License Agreement[117]. - A royalty of 10% on aggregate net sales of the product is to be paid to Merck KGaA, applicable for ten years after the first commercial sale or until the expiration of the licensed patents[118]. - The company has a Patent License Agreement with NIH, which includes a nonrefundable minimum annual royalty of $5,000 and earned royalties of 2% on net sales[122]. - Under the NCI Patent License Agreement, the company obtained a nonexclusive, worldwide license to develop TARP peptide-based therapies, with royalties and benchmark payments required[123]. - The Cooperative Research and Development Agreement with NCI includes a commitment of up to $1,000,000 for the first year and a minimum of $750,000 per year for subsequent years to support clinical research activities[126]. Market and Compliance Challenges - Coverage and reimbursement for PDS's product candidates depend on third-party payors, with significant uncertainty regarding approval and pricing processes[211]. - The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into national rebate agreements to receive federal matching funds[204]. - PDS may face civil, criminal, and administrative penalties if found in violation of healthcare laws, which could adversely affect its operations and financial results[207]. - The marketability of PDS's products may suffer if adequate coverage and reimbursement are not provided by government and third-party payors[213]. - Increased scrutiny of pharmaceutical companies by federal and state enforcement bodies may lead to investigations and compliance challenges for PDS[208]. - PDS expects ongoing pricing pressures due to managed healthcare trends and legislative changes impacting reimbursement rates[214]. - Future state and federal privacy legislation may arise, potentially impacting PDS's operations and compliance costs[210]. - Recent healthcare reforms in the U.S. may delay marketing approval for product candidates and affect sales capabilities[216]. - The Patient Protection and Affordable Care Act (PPACA) has significantly impacted healthcare financing and delivery[216].

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2022 Results Earnings Conference Call March 28, 2023 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer Conference Call Participants Leland Gershell - Oppenheimer & Co. Louise Chen - Cantor Fitzgerald Andrew Fleszar - B. Riley Securities James Molloy - Alliance Global Partners Robert LeBoyer - Noble Capital Marke ...

CFA + TARP (1-20) X Versamune® + TARP (1-20) 1 Reference: Wood LV et al, Oncoimmunology, 2016, Vol. 5 (8) CFA –Complete Freund's Adjuvant a highly potent immune activator not used in humans due to potentially lethal toxicity *Reference: Surveillance Research Program, National Cancer Institute SEER Assumes $150K for annual course of therapy; in line with current immunotherapy treatment.Assessments have not been adjusted to reflect TARP expression, which is currently unknown by tumor type 243 PDS0103: MUC1 An ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION PDS Biotechnology Corporation Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _____________ Commission file number 001-37568 Securities registered pursuant to Section 12(b) of the Act: | Ti ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2022 Results Conference Call November 14, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matt Hill - Chief Financial Officer Conference Call Participants Carvey Leung - Cantor Fitzgerald Laura Suriel - Alliance Global Partners Robert LeBoyer - Noble Capital Operator Greetings. Welcome to PDS Biotech's Third Quarter 2022 Earnings Conference Ca ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2022 Results Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald James Molloy - Alliance Global Partners Leland Gershell - Oppenheimer & Co. Joseph Pantginis - H. C. Wainwright & Co. Robert LeBoyer - Noble Capital ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _____________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) (State or othe ...